Chemotherapy compliance · patients with asymptomatic, incurable, metastatic colorectal cancer
1 finding from 1 review
Chemotherapy compliance · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy leads to lower chemotherapy compliance compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
Participants requiring chemotherapy delays · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to higher participants requiring chemotherapy delays compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Disease-free survival · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review
Induction cisplatin+5-FU+docetaxel vs cisplatin+5-FU: disease-free survival HR 0.72 (95% CI 0.57 to 0.91, P = 0.006; Vermorken 2007). Prior to concurrent chemoradiation: Posner 2007 HR 0.71 (0.56 to 0.90, P = 0.005).…
2 studies
GRADE not reported
Overall survival (total mortality), chemotherapy regimen A vs regimen B · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review
Locoregional control · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review
Toxicity / adverse effects (harms) of chemotherapy · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review
Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy may leads to higher menstruation recovery or maintenance: compared with chemotherapy alone (low certainty).
2 findings from 1 review
Premature ovarian failure · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy probably leads to lower premature ovarian failure compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Pregnancy · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy showed no clear difference in pregnancy compared with chemotherapy alone (low certainty).
1 finding from 1 review
Ovulation · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy may leads to higher ovulation compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effects: hot flush · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist plus chemotherapy changes adverse effects: hot flush compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Adverse effects: vaginal dryness · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy showed no clear difference in adverse effects: vaginal dryness compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Overall survival (non‐taxane monotherapy vs taxane monotherapy) · advanced gastric adenocarcinoma
Chemotherapy showed no clear difference in overall survival (non‐taxane monotherapy vs taxane monotherapy) compared with chemotherapy (low certainty).
1 finding from 1 review
Overall survival (taxane‐containing doublet therapy vs taxane monotherapy) · advanced gastric adenocarcinoma
Chemotherapy showed no clear difference in overall survival (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (low certainty).
1 finding from 1 review
Overall survival (non‐taxane containing therapy vs another non‐taxane containing therapy) · advanced gastric adenocarcinoma
1 finding from 1 review
Progression‐free survival (PSF) · advanced gastric adenocarcinoma
Chemotherapy showed no clear difference in progression‐free survival (non‐taxane monotherapy vs taxane… compared with chemotherapy (low certainty).
3 findings from 1 review
HR 1.14 [0.88, 1.48]
1 study · 219 participants
Low
HR 0.75 [0.52, 1.09]
2 studies · 121 participants
Low
no estimate extracted
1 study · 107 participants
High
Serious adverse effects · advanced gastric adenocarcinoma
1 finding from 1 review
Tumour response · advanced gastric adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate (non‐taxane monotherapy vs taxane monotherapy) compared with chemotherapy (low certainty).
2 findings from 1 review
Tumour response rate (taxane‐containing doublet therapy vs taxane monotherapy) · advanced gastric adenocarcinoma
It is very uncertain whether chemotherapy changes tumour response rate (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (very low certainty).
1 finding from 1 review